...
【24h】

Konjac glucomannan/xanthan gum enzyme sensitive binary mixtures for colonic drug delivery.

机译:魔芋葡甘露聚糖/黄原胶酶敏感的二元混合物,用于结肠给药。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The polysaccharide konjac glucomannan (KGM) is degraded in the colon but not the small intestine, which makes it potentially useful as an excipient for colonic drug delivery. With xanthan gum (XG) KGM forms thermoreversible gels with hitherto unexplored biodegradation properties. In this work, rheological measurements of KGM and KGM/XG systems incubated with and without Aspergillus niger beta-mannanase (used to mimic colonic enzymes) showed that KGM was degraded by the enzyme even when interacting with XG. Tablets with KGM/XG/sucrose matrices that varied in accordance with a simplex design and bore diltiazem as a typical highly soluble drug load were prepared by wet granulation, and in most cases were found to possess satisfactory mechanical strength and exhibit slow, nearly zero-order drug release. Drug release from these tablets remained zero-order, but was accelerated (presumably due to degradation of KGM), in the presence of A. niger beta-mannanase at concentrations equivalent to human colonic conditions. However, marked differences between Japanese and American varieties of KGM as regards degree of acetylation and particle size led to significant differences in swelling rate and drug release between formulations prepared with one and the other KGM: whereas a formulation with Japanese KGM released its entire drug load within 24h in the presence of beta-mannanase, only 60% release was achieved under the same conditions by the corresponding formulation with American KGM, suggesting that with this KGM it will be necessary to optimize technological variables such as compression pressure in order to achieve suitable porosity, swelling rate, and drug release. To sum up, the results of this study suggest that sustained release of water-soluble drugs in the colon from orally administered tablets may be achieved using simple, inexpensive formulations based on combinations of KGM and XG that take the variability of KGM characteristics into account.
机译:多糖魔芋葡甘露聚糖(KGM)在结肠中降解,但在小肠中不降解,这使其有可能用作结肠药物输送的赋形剂。 KGM与黄原胶(XG)形成具有迄今未开发的生物降解特性的热可逆凝胶。在这项工作中,在有和没有黑曲霉β-甘露聚糖酶(用于模拟结肠酶)下孵育的KGM和KGM / XG系统的流变学测量表明,即使与XG相互作用,KGM也会被酶降解。通过湿法制粒制备的片剂具有KGM / XG /蔗糖基质(根据单纯形设计和地尔硫卓为典型的高度可溶药物负荷)而变化的片剂,在大多数情况下,其具有令人满意的机械强度并且显示缓慢,几乎为零的状态。订购药物。在具有相当于人类结肠条件的黑曲霉β-甘露聚糖酶的存在下,从这些片剂中释放的药物保持零级,但被加速(可能是由于KGM的降解)。然而,日本和美国的KGM品种在乙酰化程度和粒径方面存在明显差异,导致使用一种和另一种KGM制备的制剂之间的溶胀速率和药物释放存在显着差异:而使用日本KGM的制剂则释放了全部药物负荷在存在β-甘露聚糖酶的情况下,在24小时内,与美国KGM配伍的制剂在相同条件下仅释放了60%,这表明,对于这种KGM,有必要优化技术变量(例如压缩压力)以实现合适的孔隙率,溶胀率和药物释放。综上所述,这项研究的结果表明,使用基于KGM和XG组合的简单,廉价制剂,并考虑到KGM特征的可变性,可以从口服片剂中实现结肠中水溶性药物的持续释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号